Home » Celator Completes Enrollment in a Second Phase II Trial of CPX-35
Celator Completes Enrollment in a Second Phase II Trial of CPX-35
Celator Pharmaceuticals Tuesday announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia in first relapse.
heraldonline
heraldonline
Upcoming Events
-
07May
-
14May
-
30May